Literature DB >> 33300045

Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.

James L Ross1,2, Zhihong Chen1,3, Cameron J Herting1,4, Yura Grabovska5, Frank Szulzewsky6, Montserrat Puigdelloses1,7, Lenore Monterroza1, Jeffrey Switchenko8, Nitin R Wadhwani9, Patrick J Cimino10, Alan Mackay5, Chris Jones5, Renee D Read11, Tobey J MacDonald1, Matthew Schniederjan12, Oren J Becher13,14,15, Dolores Hambardzumyan1,3,16.   

Abstract

Paediatric high-grade gliomas (HGGs) account for the most brain tumour-related deaths in children and have a median survival of 12-15 months. One promising avenue of research is the development of novel therapies targeting the properties of non-neoplastic cell-types within the tumour such as tumour associated macrophages (TAMs). TAMs are immunosuppressive and promote tumour malignancy in adult HGG; however, in paediatric medulloblastoma, TAMs exhibit anti-tumour properties. Much is known about TAMs in adult HGG, yet little is known about them in the paediatric setting. This raises the question of whether paediatric HGGs possess a distinct constituency of TAMs because of their unique genetic landscapes. Using human paediatric HGG tissue samples and murine models of paediatric HGG, we demonstrate diffuse midline gliomas possess a greater inflammatory gene expression profile compared to hemispheric paediatric HGGs. We also show despite possessing sparse T-cell infiltration, human paediatric HGGs possess high infiltration of IBA1+ TAMs. CD31, PDGFRβ, and PDGFB all strongly correlate with IBA1+ TAM infiltration. To investigate the TAM population, we used the RCAS/tv-a system to recapitulate paediatric HGG in newborn immunocompetent mice. Tumours are induced in Nestin-positive brain cells by PDGFA or PDGFB overexpression with Cdkn2a or Tp53 co-mutations. Tumours driven by PDGFB have a significantly lower median survival compared to PDGFA-driven tumours and have increased TAM infiltration. NanoString and quantitative PCR analysis indicates PDGFB-driven tumours have a highly inflammatory microenvironment characterized by high chemokine expression. In vitro bone marrow-derived monocyte and microglial cultures demonstrate bone marrow-derived monocytes are most responsible for the production of inflammatory signals in the tumour microenvironment in response to PDGFB stimulation. Lastly, using knockout mice deficient for individual chemokines, we demonstrate the feasibility of reducing TAM infiltration and prolonging survival in both PDGFA and PDGFB-driven tumours. We identify CCL3 as a potential key chemokine in these processes in both humans and mice. Together, these studies provide evidence for the potent inflammatory effects PDGFB has in paediatric HGGs.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PDGFB; TAM; diffuse intrinsic pontine glioma; inflammation; macrophage; paediatric glioma

Mesh:

Substances:

Year:  2021        PMID: 33300045      PMCID: PMC7954387          DOI: 10.1093/brain/awaa382

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  58 in total

1.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Authors:  Carolina Schinke; Orsolya Giricz; Weijuan Li; Aditi Shastri; Shanisha Gordon; Laura Barreyro; Laura Barreryo; Tushar Bhagat; Sanchari Bhattacharyya; Nandini Ramachandra; Matthias Bartenstein; Andrea Pellagatti; Jacqueline Boultwood; Amittha Wickrema; Yiting Yu; Britta Will; Sheng Wei; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

4.  Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.

Authors:  Zhihong Chen; Xi Feng; Cameron J Herting; Virginia Alvarez Garcia; Kai Nie; Winnie W Pong; Rikke Rasmussen; Bhakti Dwivedi; Sandra Seby; Susanne A Wolf; David H Gutmann; Dolores Hambardzumyan
Journal:  Cancer Res       Date:  2017-02-24       Impact factor: 12.701

Review 5.  Platelet-derived growth factor in human glioma.

Authors:  B Westermark; C H Heldin; M Nistér
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

Review 6.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.

Authors:  Chris Jones; Suzanne J Baker
Journal:  Nat Rev Cancer       Date:  2014-10       Impact factor: 60.716

7.  Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma.

Authors:  Victor Maximov; Zhihong Chen; Yun Wei; M Hope Robinson; Cameron J Herting; Nithya S Shanmugam; Vasilisa A Rudneva; Kelly C Goldsmith; Tobey J MacDonald; Paul A Northcott; Dolores Hambardzumyan; Anna M Kenney
Journal:  Nat Commun       Date:  2019-06-03       Impact factor: 14.919

8.  Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.

Authors:  Ioannis Kaffes; Frank Szulzewsky; Zhihong Chen; Cameron J Herting; Ben Gabanic; José E Velázquez Vega; Jennifer Shelton; Jeffrey M Switchenko; James L Ross; Leon F McSwain; Jason T Huse; Bengt Westermark; Sven Nelander; Karin Forsberg-Nilsson; Lene Uhrbom; Naga Prathyusha Maturi; Patrick J Cimino; Eric C Holland; Helmut Kettenmann; Cameron W Brennan; Daniel J Brat; Dolores Hambardzumyan
Journal:  Oncoimmunology       Date:  2019-08-22       Impact factor: 8.110

9.  Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status.

Authors:  Daphne Y S Vogel; Elly J F Vereyken; Judith E Glim; Priscilla D A M Heijnen; Martina Moeton; Paul van der Valk; Sandra Amor; Charlotte E Teunissen; Jack van Horssen; Christine D Dijkstra
Journal:  J Neuroinflammation       Date:  2013-03-04       Impact factor: 8.322

10.  Platelet-derived growth factor (PDGF)-BB-mediated induction of monocyte chemoattractant protein 1 in human astrocytes: implications for HIV-associated neuroinflammation.

Authors:  Crystal Bethel-Brown; Honghong Yao; Guoku Hu; Shilpa Buch
Journal:  J Neuroinflammation       Date:  2012-12-01       Impact factor: 8.322

View more
  12 in total

Review 1.  Role of chemokines in the crosstalk between tumor and tumor-associated macrophages.

Authors:  Rui Qin; Weihong Ren; Guoqi Ya; Bei Wang; Jiao He; Shaoxin Ren; Lu Jiang; Shuo Zhao
Journal:  Clin Exp Med       Date:  2022-09-29       Impact factor: 5.057

2.  Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.

Authors:  Nichole A Lewis; Rachel Herndon Klein; Cailin Kelly; Jennifer Yee; Paul S Knoepfler
Journal:  Epigenetics Chromatin       Date:  2022-05-19       Impact factor: 5.465

Review 3.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

4.  Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition.

Authors:  Rohit Rao; Rong Han; Sean Ogurek; Chengbin Xue; Lai Man Wu; Liguo Zhang; Li Zhang; Jian Hu; Timothy N Phoenix; Stephen N Waggoner; Q Richard Lu
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

5.  Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Authors:  Virginia Laspidea; Montserrat Puigdelloses; Sara Labiano; Lucía Marrodán; Marc Garcia-Moure; Marta Zalacain; Marisol Gonzalez-Huarriz; Naiara Martínez-Vélez; Iker Ausejo-Mauleon; Daniel de la Nava; Guillermo Herrador-Cañete; Javier Marco-Sanz; Elisabeth Guruceaga; Carlos E de Andrea; María Villalba; Oren Becher; Massimo Squatrito; Verónica Matía; Jaime Gállego Pérez-Larraya; Ana Patiño-García; Sumit Gupta; Candelaria Gomez-Manzano; Juan Fueyo; Marta M Alonso
Journal:  JCI Insight       Date:  2022-04-08

6.  Prognostic Value of the Systemic Immune-Inflammation Index and Prognostic Nutritional Index in Patients With Medulloblastoma Undergoing Surgical Resection.

Authors:  Sihan Zhu; Zhuqing Cheng; Yuanjun Hu; Zhenghe Chen; Ji Zhang; Chao Ke; Qunying Yang; Fuhua Lin; Yinsheng Chen; Jian Wang
Journal:  Front Nutr       Date:  2021-12-17

7.  A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma.

Authors:  Ping Yan; Jian-Wen Li; Li-Gen Mo; Qian-Rong Huang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

8.  An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin.

Authors:  Liat Peretz Zats; Labiba Ahmad; Natania Casden; Meelim J Lee; Vitali Belzer; Orit Adato; Shaked Bar Cohen; Seung-Hyun B Ko; Mariella G Filbin; Ron Unger; Douglas A Lauffenburger; Rosalind A Segal; Oded Behar
Journal:  Neurooncol Adv       Date:  2022-07-21

Review 9.  Tumor-Associated Microenvironment of Adult Gliomas: A Review.

Authors:  Vincenzo Di Nunno; Enrico Franceschi; Alicia Tosoni; Lidia Gatto; Stefania Bartolini; Alba Ariela Brandes
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

Review 10.  Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Authors:  Elisha Hayden; Holly Holliday; Rebecca Lehmann; Aaminah Khan; Maria Tsoli; Benjamin S Rayner; David S Ziegler
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.